Skip to content

Clinical study of contrast-enhanced ultrasound for detecting micro-blood perfusion on early diagnosis of femoral head necrosis and prediction of outcome after hip preservation

Clinical study of contrast-enhanced ultrasound for detecting micro-blood perfusion on early diagnosis of femoral head necrosis and prediction of outcome after hip preservation

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000034754
Enrollment
Unknown
Registered
2020-07-17
Start date
2020-07-30
Completion date
Unknown
Last updated
2020-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteonecrosis of the femoral head

Interventions

Gold Standard:The gold standard is MRI
The staging criteria for femoral head necrosis are based on the staging criteria established by the association research circulation osseous (2019 revision).
ultrasound

Sponsors

Department of Ultrasound, the First Affiliated Hospital of Guangzhou University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Patients who come to the orthopedics clinic and inpatient department of the First Affiliated Hospital of Guangzhou University of Chinese Medicine and meet the ONFH diagnosis of ARCO stage II and III patients; (2) Patients who underwent hip preservation surgery after femoral head necrosis; (3) The patient's age is greater than or equal to 18 years old; (4) Willing to accept conventional ultrasound and contrast-enhanced ultrasound examination, and sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients with osteoarthritis of femoral head. (2) Women who are pregnant or are preparing for pregnancy, breastfeeding women. (3) Patients with severe mental illness. (4) Patients with severe primary diseases such as liver, kidney, hematopoietic system, cardiopulmonary system, endocrine system, and malignant tumors.

Design outcomes

Primary

MeasureTime frame
Contrast-enhanced ultrasound;SEN, SPE, ACC, AUC of ROC;

Secondary

MeasureTime frame
Clinical efficacy (hip pain intensity, hip flexion function, walking distance);Imaging effect (femoral head morphology, necrosis area, osteoarthritis);

Countries

China

Contacts

Public Contactzhaoping

The First Affiliated Hospital of Guangzhou University of Chinese Medicine

zhaosiping@126.com+86 020-36588713

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026